RecallRadar

FDA Drug recall D-0816-2026

Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile…

On 2026-09-09 the FDA classified a Class II recall of Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile… by Baxter Healthcare, citing CGMP Deviations.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0816-2026
ClassificationClass II
Statusongoing
Initiated2026-08-06
Published2026-09-09
Last updated2026-09-15 05:30 UTC
CompanyBaxter Healthcare
DistributionUS

Product

Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50.

Reason

CGMP Deviations

Identifiers

ndc0338-9545-50
ndc0338-9545-24
ndc0338-9549-50
ndc0338-9549-24
ndc0338-9553-50
ndc0338-9553-24
code_infoLot # NC193689, Exp Date: 10/16/2027.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-15 05:30 UTC. Current status: ongoing.

Other recalls by Baxter Healthcare

All Baxter Healthcare recalls

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0816-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.